FDA panel backs KeraVision's corneal ring for myopia
This article was originally published in Clinica
An FDA advisory panel has unanimously recommended that the agency approves, with certain conditions, KeraVisions' implantable corneal ring for treating myopia. If approved by the FDA, Intacs (formerly called the Corneal Ring) could become the first non-laser treatment for treating people with -1.0 to -3.5 dioptres of myopia in the US.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.